These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35253814)

  • 1. Hyaluronic acid-amphotericin B nanocomplexes: a promising anti-leishmanial drug delivery system.
    Silva-Carvalho R; Leão T; Bourbon AI; Gonçalves C; Pastrana LM; Parpot P; Amorim I; Tomás AM; Gama FM
    Biomater Sci; 2022 Apr; 10(8):1952-1967. PubMed ID: 35253814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis.
    Silva-Carvalho R; Fidalgo J; Melo KR; Queiroz MF; Leal S; Rocha HA; Cruz T; Parpot P; Tomás AM; Gama M
    Int J Biol Macromol; 2020 Jun; 153():276-288. PubMed ID: 32145228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent Conjugation of Amphotericin B to Hyaluronic Acid: An Injectable Water-Soluble Conjugate with Reduced Toxicity and Anti-Leishmanial Potential.
    Silva-Carvalho R; Leão T; Gama FM; Tomás AM
    Biomacromolecules; 2022 Mar; 23(3):1169-1182. PubMed ID: 35025509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation.
    Gupta PK; Jaiswal AK; Kumar V; Verma A; Dwivedi P; Dube A; Mishra PR
    Mol Pharm; 2014 Mar; 11(3):951-63. PubMed ID: 24495144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
    de Carvalho RF; Ribeiro IF; Miranda-Vilela AL; de Souza Filho J; Martins OP; Cintra e Silva Dde O; Tedesco AC; Lacava ZG; Báo SN; Sampaio RN
    Exp Parasitol; 2013 Oct; 135(2):217-22. PubMed ID: 23891944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.
    Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM
    Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alginate-amphotericin B nanocomplexes covered by nanocrystals from bacterial cellulose: physico-chemical characterization and in vitro toxicity.
    Soeiro VS; Silva-Carvalho R; Martins D; Parpot P; Grotto D; Chaud MV; da Gama FMP; Jozala AF
    Sci Rep; 2021 Dec; 11(1):23944. PubMed ID: 34907234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.
    Golenser J; Frankenburg S; Ehrenfreund T; Domb AJ
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2209-14. PubMed ID: 10471566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B nanohydrogel ocular formulation using alkyl glyceryl hyaluronic acid: Formulation, characterization, and in vitro evaluation.
    Banshoya K; Fujita C; Hokimoto Y; Ohnishi M; Inoue A; Tanaka T; Kaneo Y
    Int J Pharm; 2021 Dec; 610():121061. PubMed ID: 34481008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions.
    Carvalheiro M; Vieira J; Faria-Silva C; Marto J; Simões S
    Drug Deliv Transl Res; 2021 Apr; 11(2):717-728. PubMed ID: 33534106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
    Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions.
    Dos Santos Matos AP; Lopes DCDXP; Peixoto MLH; da Silva Cardoso V; Vermelho AB; Santos-Oliveira R; Viçosa AL; Holandino C; Ricci-Júnior E
    Drug Deliv Transl Res; 2020 Dec; 10(6):1552-1570. PubMed ID: 32676952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations.
    Dinh T; Zia Q; Zubair S; Stapleton P; Singh R; Owais M; Somavarapu S
    Nanomedicine; 2017 Jul; 13(5):1773-1783. PubMed ID: 28216150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity.
    Kumar P; Shivam P; Mandal S; Prasanna P; Kumar S; Prasad SR; Kumar A; Das P; Ali V; Singh SK; Mandal D
    Int J Nanomedicine; 2019; 14():6073-6101. PubMed ID: 31686803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies.
    Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
    Nanomedicine (Lond); 2015; 10(7):1093-109. PubMed ID: 25929567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.